Developing and progressing therapeutic cancer vaccines
Amal Therapeutics has raised €2.8M across 1 funding round from 3 investors, most recently a Series A round in Mar 2016. Based in Geneva, Switzerland; founded 2012; active in Healthtech. Acquired by Boehringer Ingelheim in 2019. Data as of 7 Aug 2026.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2016-03-01 | Series A | €2.8M | Boehringer Ingelheim Venture Fund,High-Tech Gr√ºnderfonds (HTGF),VI Partners | View deal → |
